8 Within 3 days prior to each vac cination. 9Administered subcutaneously at 1, 2, or 4 sites ( days 1, 29, 57 all - 4 days up to +14 days. In the event a dose is delayed, all subsequent doses will be scheduled about 28 days from that dose. ) 10 Correlative / Immunology blood: 6 (10mL) green top sodium heparin tubes for PBMC; 2 (8mL) SST tubes for serum samples, and 2 (10mL) green top sodium heparin tubes for circulating tumor cell assay. 3.4 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF-STUDY CRITERIA Prior to documenting removal from protocol therapy or off study (if applicable), effort must be made to have all subjects complete a safety visit approximately 30 days following the last dose of study therapy. 37 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential 3.4.1 Criteria for Removal from Protocol T herapy Subjects will be removed from further vaccine therapy if any one of the following occurs: • Disease progression (as defined by irRC in Appendix B, Section 13.2). • Intercurrent illness or medical circumstances .